Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 6Phase 4 2Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Skin Neoplasms 1Melanoma 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 133Carboplatin 132Cisplatin 121Paclitaxel 105Gemcitabine 91Specimen Handling 82Magnetic Resonance Spectroscopy 82Docetaxel 74Dexamethasone 62Cyclophosphamide 60Pemetrexed 58Capecitabine 56Bevacizumab 56durvalumab 54Oxaliplatin 51Radiotherapy 50Doxorubicin 50Fluorouracil 49Radiation 46Leucovorin 44Rituximab 43Lenalidomide 42Vincristine 40Etoposide 38Nivolumab 37atezolizumab 36Letrozole 35130-nm albumin-bound paclitaxel 33Irinotecan 31Prednisone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × binimetinib × 90 days × Clear all
NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Pfizer

Phase 3 Active not recruiting
257 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡